nav-left cat-right
cat-right

Scil, Ono Establish Affilin Therapeutics Discovery...

Scil Proteins and Ono Pharmaceuticals signed a drug discovery collaboration focused on the development and commercialization of Affilin® molecule therapeutics in multiple disease areas. Scil will select and characterize potential Affilin candidates from its libraries for further development and commercialization by Ono. Under terms of the deal Scill will receive research funding, development and commercialization...

KINAXO’s Cellular Target Profiling® reveals mTO...

Martinsried, Germany, April 29, 2009 / b3c newswire / – Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. In addition,...

Molecular Fingerprints Point The Way To Earlier Ca...

ScienceDaily (Mar. 27, 2009) — Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer. You’ve likely heard about metabolites; your physician probably screens for some known ones such as triglycerides or cholesterol at your annual physical. Scientists suspect we have about 3,000 metabolites that come from our food or are synthesized...

AnaSpec Introduces New SensoLyteTM MMP ELISA Kits

San Jose, CA October 16, 2008 Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling. They are capable of degrading all kinds of extracellular matrix (ECM) proteins, but also can process a number of bioactive molecules. MMPs are key players in normal and pathological processes, including embryogenesis, wound healing,...

Thermo Fisher Scientific Holds European Proteomics...

SAN JOSE, Calif. (October 15, 2008) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the dates for its 2008 European Proteomics Seminar Series. The series, which takes place throughout October and November, has become an established venue for scientific and technological discussion and the sharing of practical tips. The theme of the 2008 seminar series is protein quantitation. The...

Biological Drugs Spurring an Evolution in Injectab...

(Amherst, NH) – The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and...
Page 4 of 512345